Pharmaceutical industry – Page 45
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
OpinionMessy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
BusinessChinese-made DNA sequencer aims to challenge foreign dominance
Domestic instrument pitching for a slice of the world’s fastest growing genome sequencing market
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
FeatureReaching out
Andy Extance surveys how pharma uses outsourcing in a variety of different ways
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business
Chinese police hand GSK bribery case to prosecutors
Investigation alleges senior manager ordered staff to hand out bribes
-
BusinessPfizer presses hard for AstraZeneca deal
Executives face down international controversy over tax schemes and previous post-merger record
-
BusinessBayer wins race to buy Merck & Co consumer care
$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company
-
Business
UK regulator warning over online herbal remedies
Products found to contain toxic metals or undeclared prescription-only drugs
-
Business
Insider trading allegations stall Sun–Ranbaxy deal
Companies deny wrongdoing in lead-up to merger announcement
-
Business
Forest Labs buys Furiex for bowel drug
Firm will immediately sell on other assets to Royalty Pharma
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe